Sobi Returns To Deal-Making With ADC Lymphoma Licensing Pact
Pays $55m Upfront For Rights To Zynlonta
The Swedish rare disease specialist has expanded its hematology franchise by getting the European rights to ADC Therapeutics’ Zynlonta, which has yet to make much impact commercially in the US.
You may also be interested in...
A Phase II study in a frail, older lymphoma population has seen seven respiratory-related deaths along with five other serious adverse events, but so far Zynlonta has been deemed not related to the AEs.
Public Company Edition: Seven companies revealed $2.1bn worth of royalty financings in the first quarter of 2023 and the deals keep coming in Q2, with uniQure monetizing Hemgenix royalties for up to $400m. Also, Legend grossed $350m in a follow-on offering and Athenex is liquidating via bankruptcy.
The UK firm with a presence in Boston has just emerged but Pheon’s CEO Bertrand Damour tells Scrip that big pharma is already showing interest in its next-generation antibody-drug conjugate.